Paper4402006
6 -amidinopenicillanic acids--a new group of antibiotics.
Lund F and 1 other. Nat New Biol, 1972. Cited by 200 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Download JSON
Cite this record
ConductScience Library. 6 -amidinopenicillanic acids--a new group of antibiotics. Papers, record 4402006. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4402006
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bacteria | Major topic |
| Enterobacteriaceae | Major topic |
| Penicillins | Major topic |
| Thiazoles | Major topic |
| Ampicillin | |
| Bacillus subtilis | |
| Bordetella pertussis | |
| Chromobacterium | |
| Haemophilus influenzae | |
| Microbial Sensitivity Tests | |
| Neisseria gonorrhoeae | |
| Penicillanic Acid | |
| Penicillin G | |
| Staphylococcus | |
| Streptococcus | |
| Streptococcus pneumoniae |
Source PubMed
Cited by83
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 200 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38,686,211 | A large screen identifies beta-lactam antibiotics which can be repurposed to target the syphilis agent. | NPJ Antimicrob Resist | 2023 | https://conductscience.org/library/papers/38686211 | PubMed |
| 37,660,037 | Pivmecillinam with Amoxicillin/Clavulanic acid as step down oral therapy in febrile Urinary Tract Infections caused by ESBL-producing Enterobacterales (PACUTI). | Trials | 2023 | https://conductscience.org/library/papers/37660037 | PubMed |
| 35,719,201 | In vitro activity of mecillinam, temocillin and nitroxoline against MDR Enterobacterales. | JAC Antimicrob Resist | 2022 | https://conductscience.org/library/papers/35719201 | PubMed |
| 35,590,284 | The efficacy of pivmecillinam in oral step-down treatment in hospitalised patients with E. coli bacteremic urinary tract infection; a single-arm, uncontrolled treatment study. | BMC Infect Dis | 2022 | https://conductscience.org/library/papers/35590284 | PubMed |
| 35,115,684 | Cell density-dependent antibiotic tolerance to inhibition of the elongation machinery requires fully functional PBP1B. | Commun Biol | 2022 | https://conductscience.org/library/papers/35115684 | PubMed |
| 33,510,739 | Susceptibility of Clinical Enterobacterales Isolates With Common and Rare Carbapenemases to Mecillinam. | Front Microbiol | 2020 | https://conductscience.org/library/papers/33510739 | PubMed |
| 31,332,059 | Upregulation of PBP1B and LpoB in cysB Mutants Confers Mecillinam (Amdinocillin) Resistance in Escherichia coli. | Antimicrob Agents Chemother | 2019 | https://conductscience.org/library/papers/31332059 | PubMed |
| 31,067,667 | Pivmecillinam for Uncomplicated Lower Urinary Tract Infections Caused by Staphylococcus saprophyticus-Cumulative Observational Data from Four Recent Clinical Studies. | Antibiotics (Basel) | 2019 | https://conductscience.org/library/papers/31067667 | PubMed |
| 30,917,983 | Results from a Prospective In Vitro Study on the Mecillinam (Amdinocillin) Susceptibility of Enterobacterales. | Antimicrob Agents Chemother | 2019 | https://conductscience.org/library/papers/30917983 | PubMed |
| 29,872,326 | Mecillinam for the treatment of acute pyelonephritis and bacteremia caused by Enterobacteriaceae: a literature review. | Infect Drug Resist | 2018 | https://conductscience.org/library/papers/29872326 | PubMed |
| 28,864,161 | Mecillinam - Reversion of Resistance and How to Test It. | EBioMedicine | 2017 | https://conductscience.org/library/papers/28864161 | PubMed |
| 28,855,073 | Reversion of High-level Mecillinam Resistance to Susceptibility in Escherichia coli During Growth in Urine. | EBioMedicine | 2017 | https://conductscience.org/library/papers/28855073 | PubMed |
| 27,126,213 | Classic Spotlight: Staying in Shape and Discovery of the mrdAB and mreBCD Operons. | J Bacteriol | 2016 | https://conductscience.org/library/papers/27126213 | PubMed |
| 25,583,718 | Amdinocillin (Mecillinam) resistance mutations in clinical isolates and laboratory-selected mutants of Escherichia coli. | Antimicrob Agents Chemother | 2015 | https://conductscience.org/library/papers/25583718 | PubMed |
| 24,272,507 | The molecular basis for the mode of action of Beta-lactam antibiotics and mechanisms of resistance. | Pharm Res | 1985 | https://conductscience.org/library/papers/24272507 | PubMed |
| 24,036,533 | Genome signature-based dissection of human gut metagenomes to extract subliminal viral sequences. | Nat Commun | 2013 | https://conductscience.org/library/papers/24036533 | PubMed |
| 22,216,505 | Factors influencing the absorption and disposition of mecillinam and pivmecillinam in man. | Br J Clin Pharmacol | 1976 | https://conductscience.org/library/papers/22216505 | PubMed |
| 17,725,227 | Of the morphogenes that make a ring, a rod and a sphere in Escherichia coli. | Sci Prog | 2007 | https://conductscience.org/library/papers/17725227 | PubMed |
| 8,682,786 | Mecillinam resistance in Escherichia coli is conferred by loss of a second activity of the AroK protein. | J Bacteriol | 1996 | https://conductscience.org/library/papers/8682786 | PubMed |
| 8,407,846 | Penicillin-binding protein 2 inactivation in Escherichia coli results in cell division inhibition, which is relieved by FtsZ overexpression. | J Bacteriol | 1993 | https://conductscience.org/library/papers/8407846 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/4402006
GET https://conductscience.org/api/papers/v1/4402006/cited_by?page=2